BOC Sciences Blog

PD-1

PD-1

Introduction Programmed cell death 1 (PD-1) is a costimulatory molecule that belongs to the CD28/CTLA-4 family. PD-1 recruits and activates an activation signaling pathway such as protein tyrosine phosphatase by binding […]

JAK1 inhibitor Rinvoq (upadacitinib) approved by the FDA in the United States

  Upadacitinib tartrate, a small-molecule selective inhibitor of JAK1, was recently approved in the U.S. as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) and an inadequate response […]

The first listed BTK inhibitor – Imbruvica

The first listed BTK inhibitor – Imbruvica

The sales of 2018 global small molecule drug apixaban replaced lenalidomide with a slight advantage, ranking first, and immediately after the two, it is the Imbruvica, the first listed BTK […]

Immuno-Oncology

Immuno-Oncology

The upsurge of research and development of Immuno-Oncology (IO) therapeutic drugs has been in full swing in recent years, which dominates the commanding point of public opinion in the field […]

Overview of Global approval of New drugs in July 2019

Overview of Global approval of New drugs in July 2019

In July 2019, the world’s first approval of new drugs was concentrated in the United States. The FDA (US Food and Drug Administration) approves three new molecular entity drugs (NME), […]

Hot spots in the field of drugs in July

Hot spots in the field of drugs in July

  Nat Med: a special intestinal bacteria, which is expected to reduce the risk of cardiovascular disease by 50 percent of the population. In 2007, scientists at institutions such as […]

Apixaban

Apixaban

In the past 2018, the global drug sales champion was still the macromolecular monoclonal antibody Humira (just short of $20 billion). The Top2 variety is a small molecular drug, but […]

Tyrosine kinase inhibitor dasatinib as a drug switch for CAR-T cells

Introduction of CAR-T T cells, also known as T lymphocytes, are a kind of human leukocytes, derived from bone marrow hematopoietic stem cells, mature in the thymus, and then migrate […]

Eight NMEs approved by FDA from January to June 2019

Eight NMEs approved by FDA from January to June 2019

The evaluation of drugs by FDA has always been the focus of pharmaceutical research all over the world, and the approval of NME (New molecular entity) to market is the […]

Pre-doxercalciferol

Pre-doxercalciferol is a precursor of doxercalciferol, a drug used for the treatment of secondary hyperparathyroidism and metabolic bone disease. Doxercalferol, the active ingredient of Hectorol®, is a synthetic vitamin D2 analog. […]